Compare BLND & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | EOLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.6M | 384.6M |
| IPO Year | 2021 | 2018 |
| Metric | BLND | EOLS |
|---|---|---|
| Price | $1.66 | $7.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.13 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.2M | 790.8K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $123,585,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $12.62 | $13.27 |
| Revenue Next Year | $14.00 | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $1.18 | $3.86 |
| 52 Week High | $4.49 | $7.95 |
| Indicator | BLND | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 70.42 |
| Support Level | $1.60 | $6.16 |
| Resistance Level | $2.05 | $7.76 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 68.29 | 94.70 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.